Search

Your search keyword '"Beattie, A. J."' showing total 1,354 results
Start Over Author "Beattie, A. J."
1,354 results on '"Beattie, A. J."'

5. Diagnostic accuracy of prenatal ultrasound in coarctation of aorta: systematic review and individual participant data meta‐analysis

Author

Villalaín, C., primary, D'Antonio, F., additional, Flacco, M. E., additional, Gómez‐Montes, E., additional, Herraiz, I., additional, Deiros‐Bronte, L., additional, Maskatia, S. A., additional, Phillips, A. A., additional, Contro, E., additional, Fricke, K., additional, Bhawna, A., additional, Beattie, M. J., additional, Moon‐Grady, A. J., additional, Durand, I., additional, Slodki, M., additional, Respondek‐Liberska, M., additional, Patel, C., additional, Kawamura, H., additional, Rizzo, G., additional, Pagani, G., additional, and Galindo, A., additional

Published
2024
Full Text
View/download PDF

7. Technical Note: Impact of impurities on Yttrium‐90 glass microsphere activity quantitation.

Author

Beattie, Bradley J., Kirov, Assen S., and Kesner, Adam L.

Subjects
*RADIOACTIVITY measurements, *IONIZATION chambers, *TECHNICAL specifications, *ABSORBED dose, *GLASS
Abstract

Background: Glass 90Y microspheres are produced with known radionuclide impurities. These impurities are not independently monitored. Clinical instruments, including ionization chamber dose calibrators and positron emmission tomography (PET) cameras, can be much more sensitive in detecting signals from these impurities than to signals from 90Y itself. Purpose: The "typical" levels of 90Y impurities have been studied to assess their impact on dosimetry during internal implantation, and for the management of waste. However, unaccounted‐for decay spectra of impurities can also have an impact on dose calibrator and PET readings. Thus, even what might be considered negligibly small impurity fractions, can in principle cause substantial overestimates of the amount of 90Y activity present in a sample. To our knowledge, quantitative effects of radionuclide impurities in glass microspheres on activity measurements have not been documented in the field. As activity quantitation for dosimetry and its correlations with outcome becomes more prevalent, the effects of impurities on measurements may remain unaccounted for in dosimetry studies. Methods: In this letter, we review theoretical and physical considerations that will result in asymmetric errors in quantitation from 90Y impurities and estimate their typical and potential impact on clinical utilization. Among the common impurities 88Y is of particular concern for its impact on 90Y dose measurements because of its decay characteristics, along with other isotopes 91Y and 46Sc which can also impact measurements. Results: The typical level of 88Y impurities reported by the manufacturer should only cause small errors in dose calibrator and PET measurements made within the 12‐day label‐specified use‐by period, up to 2.0% and 1.6%, respectively. However, the product specification max allowable impurity levels, specified by the manufacturer, leave open the potential for much greater bias from within the 12‐day use‐by period, potentially as high as 13.2% for dose calibrator measurements and 10.6% for PET from the 88Y impurities. Conclusions: While typical levels of impurities appear to have acceptable impact on patient absorbed dose, it should be noted that they can have adverse effects on 90Y radioactivity measurements. Furthermore, there is currently minimal independent verification and/or monitoring of impurity levels within the field. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system

Author

Bolaender, Alexander, Zatorska, Danuta, He, Huazhong, Joshi, Suhasini, Sharma, Sahil, Digwal, Chander S., Patel, Hardik J., Sun, Weilin, Imber, Brandon S., Ochiana, Stefan O., Patel, Maulik R., Shrestha, Liza, Shah, Smit. K., Wang, Shuo, Karimov, Rashad, Tao, Hui, Patel, Pallav D., Martin, Ananda Rodilla, Yan, Pengrong, Panchal, Palak, Almodovar, Justina, Corben, Adriana, Rimner, Andreas, Ginsberg, Stephen D., Lyashchenko, Serge, Burnazi, Eva, Ku, Anson, Kalidindi, Teja, Lee, Sang Gyu, Grkovski, Milan, Beattie, Bradley J., Zanzonico, Pat, Lewis, Jason S., Larson, Steve, Rodina, Anna, Pillarsetty, Nagavarakishore, Tabar, Viviane, Dunphy, Mark P., Taldone, Tony, Shimizu, Fumiko, and Chiosis, Gabriela

Published
2021
Full Text
View/download PDF

21. Supplemental Figure 5 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Author

Dunphy, Mark P.S., primary, Pressl, Christina, primary, Pillarsetty, Nagavarakishore, primary, Grkovski, Milan, primary, Modi, Shanu, primary, Jhaveri, Komal, primary, Norton, Larry, primary, Beattie, Bradley J., primary, Zanzonico, Pat B., primary, Zatorska, Danuta, primary, Taldone, Tony, primary, Ochiana, Stefan O., primary, Uddin, Mohammad M., primary, Burnazi, Eva M., primary, Lyashchenko, Serge K., primary, Hudis, Clifford A., primary, Bromberg, Jacqueline, primary, Schöder, Heiko M., primary, Fox, Josef J., primary, Zhang, Hanwen, primary, Chiosis, Gabriela, primary, Lewis, Jason S., primary, and Larson, Steven M., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Data from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Author

Dunphy, Mark P.S., primary, Pressl, Christina, primary, Pillarsetty, Nagavarakishore, primary, Grkovski, Milan, primary, Modi, Shanu, primary, Jhaveri, Komal, primary, Norton, Larry, primary, Beattie, Bradley J., primary, Zanzonico, Pat B., primary, Zatorska, Danuta, primary, Taldone, Tony, primary, Ochiana, Stefan O., primary, Uddin, Mohammad M., primary, Burnazi, Eva M., primary, Lyashchenko, Serge K., primary, Hudis, Clifford A., primary, Bromberg, Jacqueline, primary, Schöder, Heiko M., primary, Fox, Josef J., primary, Zhang, Hanwen, primary, Chiosis, Gabriela, primary, Lewis, Jason S., primary, and Larson, Steven M., primary

Published
2023
Full Text
View/download PDF

23. Supplemental Figure 2 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Author

Dunphy, Mark P.S., primary, Pressl, Christina, primary, Pillarsetty, Nagavarakishore, primary, Grkovski, Milan, primary, Modi, Shanu, primary, Jhaveri, Komal, primary, Norton, Larry, primary, Beattie, Bradley J., primary, Zanzonico, Pat B., primary, Zatorska, Danuta, primary, Taldone, Tony, primary, Ochiana, Stefan O., primary, Uddin, Mohammad M., primary, Burnazi, Eva M., primary, Lyashchenko, Serge K., primary, Hudis, Clifford A., primary, Bromberg, Jacqueline, primary, Schöder, Heiko M., primary, Fox, Josef J., primary, Zhang, Hanwen, primary, Chiosis, Gabriela, primary, Lewis, Jason S., primary, and Larson, Steven M., primary

Published
2023
Full Text
View/download PDF

24. Supplemental Figure 4 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Author

Dunphy, Mark P.S., primary, Pressl, Christina, primary, Pillarsetty, Nagavarakishore, primary, Grkovski, Milan, primary, Modi, Shanu, primary, Jhaveri, Komal, primary, Norton, Larry, primary, Beattie, Bradley J., primary, Zanzonico, Pat B., primary, Zatorska, Danuta, primary, Taldone, Tony, primary, Ochiana, Stefan O., primary, Uddin, Mohammad M., primary, Burnazi, Eva M., primary, Lyashchenko, Serge K., primary, Hudis, Clifford A., primary, Bromberg, Jacqueline, primary, Schöder, Heiko M., primary, Fox, Josef J., primary, Zhang, Hanwen, primary, Chiosis, Gabriela, primary, Lewis, Jason S., primary, and Larson, Steven M., primary

Published
2023
Full Text
View/download PDF

25. Supplemental Figure 1 from First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer

Author

Dunphy, Mark P.S., primary, Pressl, Christina, primary, Pillarsetty, Nagavarakishore, primary, Grkovski, Milan, primary, Modi, Shanu, primary, Jhaveri, Komal, primary, Norton, Larry, primary, Beattie, Bradley J., primary, Zanzonico, Pat B., primary, Zatorska, Danuta, primary, Taldone, Tony, primary, Ochiana, Stefan O., primary, Uddin, Mohammad M., primary, Burnazi, Eva M., primary, Lyashchenko, Serge K., primary, Hudis, Clifford A., primary, Bromberg, Jacqueline, primary, Schöder, Heiko M., primary, Fox, Josef J., primary, Zhang, Hanwen, primary, Chiosis, Gabriela, primary, Lewis, Jason S., primary, and Larson, Steven M., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure Legends 1-4 from Imaging Transgene Activity In vivo

Author

Gade, Terence P.F., primary, Koutcher, Jason A., primary, Spees, William M., primary, Beattie, Bradley J., primary, Ponomarev, Vladimir, primary, Doubrovin, Michael, primary, Buchanan, Ian M., primary, Beresten, Tatiana, primary, Zakian, Kristen L., primary, Le, H. Carl, primary, Tong, William P., primary, Mayer-Kuckuk, Philipp, primary, Blasberg, Ronald G., primary, and Gelovani, Juri G., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 3 from Imaging Transgene Activity In vivo

Author

Gade, Terence P.F., primary, Koutcher, Jason A., primary, Spees, William M., primary, Beattie, Bradley J., primary, Ponomarev, Vladimir, primary, Doubrovin, Michael, primary, Buchanan, Ian M., primary, Beresten, Tatiana, primary, Zakian, Kristen L., primary, Le, H. Carl, primary, Tong, William P., primary, Mayer-Kuckuk, Philipp, primary, Blasberg, Ronald G., primary, and Gelovani, Juri G., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 1 from Imaging Transgene Activity In vivo

Author

Gade, Terence P.F., primary, Koutcher, Jason A., primary, Spees, William M., primary, Beattie, Bradley J., primary, Ponomarev, Vladimir, primary, Doubrovin, Michael, primary, Buchanan, Ian M., primary, Beresten, Tatiana, primary, Zakian, Kristen L., primary, Le, H. Carl, primary, Tong, William P., primary, Mayer-Kuckuk, Philipp, primary, Blasberg, Ronald G., primary, and Gelovani, Juri G., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 4 from Imaging Transgene Activity In vivo

Author

Gade, Terence P.F., primary, Koutcher, Jason A., primary, Spees, William M., primary, Beattie, Bradley J., primary, Ponomarev, Vladimir, primary, Doubrovin, Michael, primary, Buchanan, Ian M., primary, Beresten, Tatiana, primary, Zakian, Kristen L., primary, Le, H. Carl, primary, Tong, William P., primary, Mayer-Kuckuk, Philipp, primary, Blasberg, Ronald G., primary, and Gelovani, Juri G., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Figure 2 from Imaging Transgene Activity In vivo

Author

Gade, Terence P.F., primary, Koutcher, Jason A., primary, Spees, William M., primary, Beattie, Bradley J., primary, Ponomarev, Vladimir, primary, Doubrovin, Michael, primary, Buchanan, Ian M., primary, Beresten, Tatiana, primary, Zakian, Kristen L., primary, Le, H. Carl, primary, Tong, William P., primary, Mayer-Kuckuk, Philipp, primary, Blasberg, Ronald G., primary, and Gelovani, Juri G., primary

Published
2023
Full Text
View/download PDF

31. Data from Imaging Transgene Activity In vivo

Author

Gade, Terence P.F., primary, Koutcher, Jason A., primary, Spees, William M., primary, Beattie, Bradley J., primary, Ponomarev, Vladimir, primary, Doubrovin, Michael, primary, Buchanan, Ian M., primary, Beresten, Tatiana, primary, Zakian, Kristen L., primary, Le, H. Carl, primary, Tong, William P., primary, Mayer-Kuckuk, Philipp, primary, Blasberg, Ronald G., primary, and Gelovani, Juri G., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results